European shares trimmed morning gains on Wednesday as continuing geopolitical tensions in Ukraine hit sentiment.

The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

European shares made a strong start on Wednesday despite an unexpected spike in UK inflation and continuing geopolitical tensions.

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and ...

Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board ...

Spanish drug maker Grifols said its board would hold an extraordinary meeting to review Brookfield Capital Partners' offer to take the company private, adding that its transaction committee considers ...

Citigroup Inc and Banco Santander SA are readying a debt package of up to €4 billion ($4.2 billion) to back a potential sale ...